ArticleArthritis research & therapy2026
Targeting the SARM1-cADPR-Ca
Article in Arthritis research & therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
introductionOsteoarthritis (OA) is a prevalent degenerative joint disease accompanied by increased number of senescent chondrocytes. Mitochondrial dysfunction is a well-established hallmark of chondrocyte senescence in OA pathogenesis. Sterile α and Toll/Interleukin-1 Receptor motif-containing 1 (SARM1), known to drive mitochondrial impairment in various cell types, has not been thoroughly investigated in the context of chondrocyte aging or OA.
methodsWe established a doxorubicin (DOX)-induced senescence model in primary mouse chondrocytes. Gain- and loss-of-function approaches were employed using siRNA-mediated knockdown and lentiviral overexpression of SARM1, followed by assessment of senescence markers, mitochondrial function, and morphology. To investigate the mechanistic pathway, exogenous cyclic ADP-ribose (cADPR) and its specific inhibitor 8-Br-cADPR were applied, with subsequent evaluation of intracellular calcium dynamics and Drp1 translocation to mitochondria. We next tested the efficacy of blocking this SARM1/cADPR axis both ex vivo on human femoral head tissue as well as in an experimental OA mouse model.
resultsChondrocytes isolated from human OA cartilage and aged murine cartilage showed increased expression of SARM1. Knockdown of SARM1 reduced DOX-induced chondrocyte senescence and mitochondrial dysfunction, while overexpression of wild-type but not catalytic-inactive SARM1-TIR domain mutant (TIR-E642A) induced intrinsic apoptosis and mitochondrial fragmentation. Exogenous cADPR recapitulated senescence and mitochondrial fragmentation, whereas treatment with 8-Br-cADPR abolished SARM1-dependent effects. Mechanistically, SARM1-generated cADPR increased intracellular calcium levels, triggering Drp1 phosphorylation at Ser616 and dephosphorylation at Ser637, thereby resulting in Drp1-FIS1 interaction and mitochondrial fission. Interestingly, pharmacological or genetic inhibition of the SARM1/cADPR pathway ameliorated cartilage degradation in the experimental OA model.
conclusionWe show that SARM1 mediates mitochondrial fragmentation by activating cADPR-dependent calcium signaling, which in turn promotes Drp1 binding to FIS1. This suggests an unappreciated role for the SARM1-cADPR pathway in OA etiology and presents this pathway as an attractive candidate to be targeted therapeutically.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.